Key result
Fibrinolysis raises major extracranial bleeding risk by ~11 percentage points in elderly intermediate-risk PE.
Why the study?
The safety and timing of anticoagulation initiation, specifically the omission of an initial bolus of unfractionated heparin before low-molecular-weight heparin in intermediate-risk pulmonary embolism patients, was uncertain and may affect hemodynamic outcomes.
Answers are grounded in this paper and cite their sources.
Supports withholding fibrinolysis in patients >75 years with intermediate-risk PE; leaves open optimal age-specific reperfusion strategies.
To the Editor: In the Pulmonary Embolism Thrombolysis (PEITHO) study (April 10 issue),1 a bolus of unfractionated heparin was withheld from 303 patients because they had just received subcutaneous low-molecular-weight heparin or fondaparinux. Low-molecular-weight heparin in particular has a slow onset of action, taking 4 to 6 hours to reach full effect.2 This delay in the effect of treatment may have been unfavorable to patients not receiving tenecteplase, among whom the incidence of hemodynamic decompensation (often within the first day after randomization) was higher than that among patients receiving tenecteplase. Guidelines support the safety of low-molecularweight heparin in patients with pulmonary embolism. Caution is warranted, however, because the majority of relevant trials (10 of 12 trials in a key meta-analysis3) used low-molecular-weight heparin after an initial bolus of unfractionated heparin. Omitting this bolus may be unsafe, particularly in high-risk patients such as those involved in the PEITHO study. Previous guidelines have recommended a bolus of unfractionated heparin before the administration of lowmolecular-weight heparin.4 Later, for some reason, this recommendation disappeared. We would like to know outcome details of the subgroup of patients who did not receive an initial bolus of unfractionated heparin. If hemodynamic decompensation in the placebo group occurred primarily in this subgroup, the explanation may be a delayed onset of anticoagulant activity. Yvo Smulders, M.D.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2014) conducted a letter in Intermediate-risk pulmonary embolism (n=1,005). Fibrinolysis vs. Placebo was evaluated on Major extracranial bleeding in patients >75 years of age (OR 20.38, 95% CI 5.5 to 15.5, p=0.09). In patients older than 75 years with intermediate-risk pulmonary embolism, fibrinolysis increased the absolute risk of major extracranial bleeding by 10.5 percentage points compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: